Back to top

rsi: Archive

Zacks Equity Research

Down 10.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Interpublic (IPG)

The heavy selling pressure might have exhausted for Interpublic (IPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

IPGPositive Net Change

Zacks Equity Research

Gauzy Ltd. (GAUZ) Loses 19.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Gauzy Ltd. (GAUZ) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

GAUZPositive Net Change

Zacks Equity Research

Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround

Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SMMTPositive Net Change

Zacks Equity Research

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

OMERNo Net Change

Zacks Equity Research

Criteo (CRTO) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Criteo (CRTO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

CRTONegative Net Change

Zacks Equity Research

After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)

Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SERANegative Net Change

Zacks Equity Research

Oxford Square Capital (OXSQ) Loses 7.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Oxford Square Capital (OXSQ) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

OXSQPositive Net Change

Zacks Equity Research

Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)

The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

PIIINegative Net Change

Zacks Equity Research

After Plunging 10.87% in 4 Weeks, Here's Why the Trend Might Reverse for Cervecerias Unidas (CCU)

Cervecerias Unidas (CCU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

CCUNegative Net Change

Zacks Equity Research

AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AXGNNegative Net Change

Zacks Equity Research

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SRZNPositive Net Change

Zacks Equity Research

After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)

Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

INGNPositive Net Change

Zacks Equity Research

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

ALLONegative Net Change

Zacks Equity Research

Down -9.16% in 4 Weeks, Here's Why Exelon (EXC) Looks Ripe for a Turnaround

Exelon (EXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

EXCNegative Net Change

Zacks Equity Research

After Plunging -5.25% in 4 Weeks, Here's Why the Trend Might Reverse for New Jersey Resources (NJR)

The heavy selling pressure might have exhausted for New Jersey Resources (NJR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

NJRPositive Net Change

Zacks Equity Research

Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

TARSNegative Net Change

Zacks Equity Research

Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround

Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SERANegative Net Change

Zacks Equity Research

Down -57.05% in 4 Weeks, Here's Why You Should You Buy the Dip in AZUL (AZUL)

The heavy selling pressure might have exhausted for AZUL (AZUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

MYGNPositive Net Change

Zacks Equity Research

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

PHATNegative Net Change

Zacks Equity Research

Down -20.26% in 4 Weeks, Here's Why LifeStance Health (LFST) Looks Ripe for a Turnaround

LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

LFSTPositive Net Change

Zacks Equity Research

Here's Why HealthStream (HSTM) is Poised for a Turnaround After Losing -13.2% in 4 Weeks

HealthStream (HSTM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

HSTMNegative Net Change

Zacks Equity Research

Prairie Operating Co. (PROP) Loses -36.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Prairie Operating Co. (PROP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PROPPositive Net Change

Zacks Equity Research

After Plunging -26.98% in 4 Weeks, Here's Why the Trend Might Reverse for Iridium (IRDM)

Iridium (IRDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

IRDMPositive Net Change

Zacks Equity Research

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

ESPRNegative Net Change